KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Accumulated Expenses: 2011-2025

Historic Other Accumulated Expenses for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $10.2 million.

  • Sarepta Therapeutics' Other Accumulated Expenses fell 40.78% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 40.78%. This contributed to the annual value of $13.5 million for FY2024, which is 24.50% down from last year.
  • As of Q3 2025, Sarepta Therapeutics' Other Accumulated Expenses stood at $10.2 million, which was down 1.70% from $10.4 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Other Accumulated Expenses high stood at $26.2 million for Q3 2022, and its period low was $5.3 million during Q4 2022.
  • Over the past 3 years, Sarepta Therapeutics' median Other Accumulated Expenses value was $17.0 million (recorded in 2023), while the average stood at $15.3 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Other Accumulated Expenses tumbled by 64.69% in 2022, and later soared by 235.81% in 2023.
  • Sarepta Therapeutics' Other Accumulated Expenses (Quarterly) stood at $15.1 million in 2021, then crashed by 64.69% to $5.3 million in 2022, then spiked by 235.81% to $17.8 million in 2023, then dropped by 24.50% to $13.5 million in 2024, then tumbled by 40.78% to $10.2 million in 2025.
  • Its Other Accumulated Expenses stands at $10.2 million for Q3 2025, versus $10.4 million for Q2 2025 and $13.0 million for Q1 2025.